Journal of Drug Targeting最新文献_第3页

Photodynamic and sonodynamic therapy synergy: mechanistic insights and cellular responses against glioblastoma multiforme. 光动力和声动力疗法的协同作用：对多形性胶质母细胞瘤的机理认识和细胞反应。

IF 4.3 4区医学

Journal of Drug Targeting Pub Date : 2025-04-01 Epub Date: 2024-11-26 DOI: 10.1080/1061186X.2024.2431676

Swati Sharma, Geetanjali B Gone, Parikshit Roychowdhury, Hyung Sik Kim, Sang Jeon Chung, Gowthmarajan Kuppusamy, Anindita De

{"title":"Photodynamic and sonodynamic therapy synergy: mechanistic insights and cellular responses against glioblastoma multiforme.","authors":"Swati Sharma, Geetanjali B Gone, Parikshit Roychowdhury, Hyung Sik Kim, Sang Jeon Chung, Gowthmarajan Kuppusamy, Anindita De","doi":"10.1080/1061186X.2024.2431676","DOIUrl":"10.1080/1061186X.2024.2431676","url":null,"abstract":"Glioblastoma multiforme (GBM), the most aggressive form of brain cancer, poses substantial challenges to effective treatment due to its complex and infiltrative nature, making it difficult to manage. Photodynamic therapy (PDT) and sonodynamic therapy (SDT), have emerged as promising individual treatment options against GBM due to their least-invasive approach. However, both PDT and SDT have drawbacks that require careful consideration. A combination therapy using light and sound waves has gained attention, offering new avenues to overcome challenges from individual therapies. Sono-photodynamic therapy (SPDT) has been used against various tumours. Researchers are considering SPDT as a favourable alternative to the conventional therapies for GBM. SPDT offers complementary mechanisms of action, including the production of ROS, disruption of cellular structures, and induction of apoptosis, leading to enhanced tumour cell death. This review gives an insight about PDT/SDT and their limitations in GBM treatment and the need for combination therapy. We try to unveil the process of SPDT and explore the mechanism behind improved SPDT-meditated cell death in GBM cells by focusing on the ROS-mediated cell response occurring as a result of SPDT and discussing current modifications in the existing sensitisers for their optimal use in SPDT for GBM therapy.","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"458-472"},"PeriodicalIF":4.3,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142667940","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Development of in vitro and in vivo evaluation of mucoadhesive in-situ gel for intranasal delivery of vinpocetine. 开发用于鼻内输送长春西汀的粘液黏附性原位凝胶的体外和体内评估。

IF 4.3 4区医学

Journal of Drug Targeting Pub Date : 2025-04-01 Epub Date: 2024-11-27 DOI: 10.1080/1061186X.2024.2433557

Sumaia Abdulbari Ahmed Ali Hard, H N Shivakumar, Duaa Abdullah Bafail, Moqbel Ali Moqbel Redhwan

{"title":"Development of in vitro and in vivo evaluation of mucoadhesive in-situ gel for intranasal delivery of vinpocetine.","authors":"Sumaia Abdulbari Ahmed Ali Hard, H N Shivakumar, Duaa Abdullah Bafail, Moqbel Ali Moqbel Redhwan","doi":"10.1080/1061186X.2024.2433557","DOIUrl":"10.1080/1061186X.2024.2433557","url":null,"abstract":"ABSTRACT Alzheimer's disease (AD), which is marked by gradual neuronal decline and subsequent loss of cognitive functions and memory, poses significant treatment challenges. The present study involved the development, in vitro, and in vivo evaluation of a novel intranasal mucoadhesive in-situ gel of vinpocetine (VIN) with the aim to target the brain. An innovative gel formulation composed of poloxamer 407, HPMC E15 LV, and citric acid as a solubilizer was developed by 23 Factorial Design. The developed optimal formulation exhibited favorable rheological properties as it displayed ideal gelation time (31.6 ± 1.52 sec), optimum gelling temperature (32 ± 1.0 °C), enhanced mucoadhesive strength (6622 ± 2.64 dynes/cm2), prolonged adhesion (7.22 ± 0.57 hrs) compared with the baseline formulation (F18), and improved drug release in 12 hrs (39.59 ± 1.6%). In vivo, pharmacokinetics revealed a significant increase in Cmax (∼2-fold) and AUC0-t (∼2-fold) in the brain with the in-situ intranasal gel compared to the oral route. In the rat model of AD, in-situ intranasal gel demonstrated significantly greater efficacy (p < 0.001) than oral administration in alleviating AD symptoms as evidenced by behavioral and histological studies. Thus, VIN in-situ gel can be safe and noninvasive for nose-to-brain drug delivery.","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"528-545"},"PeriodicalIF":4.3,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142729353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advances in nano-delivery systems based on diagnosis and theranostics strategy for atherosclerosis. 基于动脉粥样硬化诊断和治疗策略的纳米输送系统的进展。

IF 4.3 4区医学

Journal of Drug Targeting Pub Date : 2025-04-01 Epub Date: 2024-11-27 DOI: 10.1080/1061186X.2024.2433560

Xi Yang, Jian Hu, Quanle Gao, Yiping Deng, Yilin Liu, Xinghui He, Chuang Li, Xin Yu, Ying Wan, Chao Pi, Yumeng Wei, Chunhong Li

{"title":"Advances in nano-delivery systems based on diagnosis and theranostics strategy for atherosclerosis.","authors":"Xi Yang, Jian Hu, Quanle Gao, Yiping Deng, Yilin Liu, Xinghui He, Chuang Li, Xin Yu, Ying Wan, Chao Pi, Yumeng Wei, Chunhong Li","doi":"10.1080/1061186X.2024.2433560","DOIUrl":"10.1080/1061186X.2024.2433560","url":null,"abstract":"Atherosclerosis (AS) is a chronic systemic inflammatory disease, where early diagnosis and theranostics strategy for AS are crucial for improving outcomes. However, conventional diagnostic techniques are limited in identifying early AS lesions, failing to stop the progression of AS in time. Nano-delivery systems have shown significant potential in AS diagnosis and treatment, offering distinct advantages in plaque identification and enhancing drugs concentration at lesion sites, thereby advancing new-generation theranostics strategy. This review discusses the application of nano-delivery systems based on imaging technology in AS diagnosis, and we further explore recent advancements in combining different imaging technologies with emerging theranostics strategy. In addition, we also discuss the challenges faced by nano-delivery systems for AS diagnosis and theranostics in clinical translation, such as nanoparticle targeting efficiency, cytotoxicity and long-term accumulation, immune clearance and inaccurate disease modelling. Finally, we also provide prospects on nano-delivery systems based on diagnostic and therapeutic strategies.","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"492-507"},"PeriodicalIF":4.3,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142729325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Artificial intelligence-based molecular property prediction of photosensitising effects of drugs. 基于人工智能的药物光敏效应分子性质预测。

IF 4.3 4区医学

Journal of Drug Targeting Pub Date : 2025-04-01 Epub Date: 2024-12-02 DOI: 10.1080/1061186X.2024.2434911

Amun G Hofmann, Benedikt Weber, Sally Ibbotson, Asan Agibetov

{"title":"Artificial intelligence-based molecular property prediction of photosensitising effects of drugs.","authors":"Amun G Hofmann, Benedikt Weber, Sally Ibbotson, Asan Agibetov","doi":"10.1080/1061186X.2024.2434911","DOIUrl":"10.1080/1061186X.2024.2434911","url":null,"abstract":"Drug-induced photosensitivity is a potential adverse event of many drugs and chemicals used across a wide range of specialties in clinical medicine. In the present study, we investigated the feasibility of predicting the photosensitising effects of drugs and chemical compounds via state-of-the-art artificial intelligence-based workflows. A dataset of 2200 drugs was used to train three distinct models (logistic regression, XGBoost and a deep learning model (Chemprop)) to predict photosensitising attributes. Labels were obtained from a list of previously published photosensitisers by string matching and manual validation. External evaluation of the different models was performed using the tox21 dataset. ROC-AUC ranged between 0.8939 (Chemprop) and 0.9525 (XGBoost) during training, while in the test partition it ranged between 0.7785 (Chemprop) and 0.7927 (XGBoost). Analysis of the top 200 compounds of each model resulted in 55 overlapping molecules in the external validation set. Prediction scores in fluoroquinolones within this subset corresponded well with culprit substructures such as fluorinated aryl halides suspected of mediating photosensitising effects. All three models appeared capable of predicting photosensitising effects of chemical compounds. However, compared to the simpler model, the complex models appeared to be more confident in their predictions as exhibited by their distribution of prediction scores.","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"556-561"},"PeriodicalIF":4.3,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142769291","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Nanoparticle-Based gene therapy strategies in retinal delivery. 基于纳米粒子的视网膜传递基因治疗策略。

IF 4.3 4区医学

Journal of Drug Targeting Pub Date : 2025-04-01 Epub Date: 2025-01-03 DOI: 10.1080/1061186X.2024.2433563

Thomas Foster, Patrick Lim, Susbin Raj Wagle, Corina Mihaela Ionescu, Bozica Kovacevic, Samuel McLenachan, Livia Carvalho, Alicia Brunet, Armin Mooranian, Hani Al-Salami

引用次数: 0

Selection of LRP1 ligand phage-displayed single domain antibody that transmigrates BBB. LRP1配体噬菌体显示的血脑屏障单结构域抗体的选择。

IF 4.3 4区医学

Journal of Drug Targeting Pub Date : 2025-04-01 Epub Date: 2024-12-02 DOI: 10.1080/1061186X.2024.2434908

Viana Manrique-Suárez, Bryan A Mangui Catota, Frank Camacho Casanova, Nery A Jara Mendoza, Maria A Contreras Vera, Rafael Maura Pérez, Fátima Reyes López, Roberto Toledo Alonso, Pablo Ignacio Castro Henriquez, Oliberto Sánchez Ramos

{"title":"Selection of LRP1 ligand phage-displayed single domain antibody that transmigrates BBB.","authors":"Viana Manrique-Suárez, Bryan A Mangui Catota, Frank Camacho Casanova, Nery A Jara Mendoza, Maria A Contreras Vera, Rafael Maura Pérez, Fátima Reyes López, Roberto Toledo Alonso, Pablo Ignacio Castro Henriquez, Oliberto Sánchez Ramos","doi":"10.1080/1061186X.2024.2434908","DOIUrl":"10.1080/1061186X.2024.2434908","url":null,"abstract":"Effective drug delivery to the central nervous system (CNS) remains a challenge due to the blood-brain barrier (BBB). Macromolecules such as proteins and peptides are unable to cross BBB and have poor therapeutic efficacy due to little or no drug distribution. A promising alternative is the conjugation of a drug to a shuttle molecule that can reach the CNS via receptor-mediated transcytosis (RMT). Several receptors have been described for RMT, such as low-density lipoprotein receptor-related protein 1 (LRP1). We used phage display technology combined with an in vitro BBB model to identify LRP1 ligands. A single domain antibody (dAb) library was used to enrich for species that selectively bind to immobilised LRP1 ligand. We obtained a novel nanobody, dAb D11, that selectively binds to LRP1 receptor and mediates in vitro internalisation of phage particles in brain endothelial cells, with a dissociation constant Kd of 183.1 ± 85.8 nM. The high permeability of D11 was demonstrated by an in vivo biodistribution assay in mice. We discovered D11, the first LRP1 binding dAb with BBB permeability. Our findings will contribute to the development of RMT-based drugs for the treatment of CNS diseases.","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"546-555"},"PeriodicalIF":4.3,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142769223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Methodological advances in liposomal encapsulation efficiency determination: systematic review and analysis.

IF 4.3 4区医学

Journal of Drug Targeting Pub Date : 2025-03-31 DOI: 10.1080/1061186X.2025.2484773

Jin-Ping Wang, Zi-Rui Huang, Cheng Zhang, Yi-Ran Ni, Bo-Tao Li, Ying Wang, Jiang-Feng Wu

{"title":"Methodological advances in liposomal encapsulation efficiency determination: systematic review and analysis.","authors":"Jin-Ping Wang, Zi-Rui Huang, Cheng Zhang, Yi-Ran Ni, Bo-Tao Li, Ying Wang, Jiang-Feng Wu","doi":"10.1080/1061186X.2025.2484773","DOIUrl":"10.1080/1061186X.2025.2484773","url":null,"abstract":"Liposomes represent a highly promising drug delivery platform for a wide range of pharmaceutical compounds. Encapsulation efficiency (EE) stands as a critical quality attribute for liposomal formulations. Accurate determination of EE requires quantification of at least two parameters among the three distinct drug populations: total drug content, encapsulated drug fraction, and free drug concentration. However, due to the complex physicochemical characteristics of liposomes, particularly their structural flexibility, surface charge properties, and organic phase composition, direct measurement of encapsulated and free drug fractions presents significant analytical challenges. The ability to precisely quantify both free and total drug concentrations in liposomal formulations enables rapid and reliable evaluation of encapsulation efficiency, which is essential for guiding formulation optimisation and ensuring consistent product quality during scale-up manufacturing processes. This review provides a comprehensive analysis of various analytical techniques for EE determination, including (reverse) dialysis, ultrafiltration centrifugation, differential centrifugation (ultra/low-speed), and size exclusion chromatography, with particular emphasis on their methodological characteristics, applicable ranges, advantages, and limitations. Furthermore, we propose appropriate detection strategies for encapsulation efficiency assessment based on specific laboratory capabilities and the physicochemical properties of the investigational compounds.","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"1-10"},"PeriodicalIF":4.3,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143692352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Understanding the role of Ethosomes in Rheumatoid Arthritis: Innovative Solutions to Challenges in Transdermal Delivery of Synthetic Drugs and Phytoconstituents.

IF 4.3 4区医学

Journal of Drug Targeting Pub Date : 2025-03-20 DOI: 10.1080/1061186X.2025.2477068

Rohan Anchan, Anish Ghadi, Mohammed Ali Chauhan, Angel Godad, Sankalp Gharat

{"title":"Understanding the role of Ethosomes in Rheumatoid Arthritis: Innovative Solutions to Challenges in Transdermal Delivery of Synthetic Drugs and Phytoconstituents.","authors":"Rohan Anchan, Anish Ghadi, Mohammed Ali Chauhan, Angel Godad, Sankalp Gharat","doi":"10.1080/1061186X.2025.2477068","DOIUrl":"https://doi.org/10.1080/1061186X.2025.2477068","url":null,"abstract":"Rheumatoid Arthritis (RA), an autoimmune disease, is a chronic inflammatory disorder affecting the joints leading to severe damage and cartilage destruction. Current therapies for RA such as DMARDs, NSAIDs, glucocorticoids, and phytoconstituents often face challenges related to solubility and transdermal permeability. Considering the barriers posed by the stratum corneum in transdermal drug delivery, ethosomes have shown promising results in overcoming these hurdles. The presence of ethanol in ethosomes imparts flexibility and disrupts the skin's lipid bilayer, allowing for transdermal penetration. Researchers have explored the potential of ethosomal drug delivery systems loaded with various synthetic drugs and phytoconstituents for the management of RA. Despite promising preclinical findings, these systems have yet to transition from the bench to the bedside, and there is a lack of comprehensive review papers highlighting the potential of ethosomes in RA treatment. Considering the commercial challenges in scaling up such nano systems, this review aims to analyse the current state of the art and advancements in ethosomal formulations loaded with synthetic agents and phytoconstituents. Further, it explores the impact of excipients and processing parameters, on the preparation of ethosomes and their efficacy in overcoming skin barriers, to enhance the permeability of therapeutic agents.","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"1-27"},"PeriodicalIF":4.3,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143669931","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Redefining hepatocellular carcinoma treatment: nanotechnology meets tumor immune microenvironment.

IF 4.3 4区医学

Journal of Drug Targeting Pub Date : 2025-03-17 DOI: 10.1080/1061186X.2025.2479757

Chuanliang Mi, Sai Liu, Zhida Chen

{"title":"Redefining hepatocellular carcinoma treatment: nanotechnology meets tumor immune microenvironment.","authors":"Chuanliang Mi, Sai Liu, Zhida Chen","doi":"10.1080/1061186X.2025.2479757","DOIUrl":"10.1080/1061186X.2025.2479757","url":null,"abstract":"Hepatocellular carcinoma (HCC) is one of the most lethal malignancies worldwide, characterised by its complex pathogenesis and poor therapeutic outcomes. Despite recent advances in targeted molecular therapies, immune checkpoint inhibitors (ICIs), radiotherapy and conventional chemotherapy, the 5-year survival rate for this neoplasm remains dismally low. The progress in nanotechnology has revolutionised cancer treatment in recent years. These advances provide unprecedented opportunities to overcome the current limitations of different therapeutic modalities. This review provides a comprehensive analysis of how nanotechnology interfaces with the tumour immune microenvironment (TIME) in HCC and can present a new frontier in therapeutic interventions for HCC. We critically overview the latest developments in nanoparticle-based delivery systems for various drugs and also other antitumor agents like thermal therapy and radiotherapy. We also highlight the unique ability of nanoparticles to modulate the immunosuppressive tumour microenvironment (TME) and enhance therapeutic efficacy. Furthermore, we analyse emerging strategies that exploit nanoformulations to overcome biological barriers and enhance drug bioavailability in HCC treatment.","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"1-20"},"PeriodicalIF":4.3,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143624972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cell-based immunotherapy in oesophageal cancer.

IF 4.3 4区医学

Journal of Drug Targeting Pub Date : 2025-03-17 DOI: 10.1080/1061186X.2025.2477077

Masoud Lahouty, Amirhossein Soleymanzadeh, Sama Kazemi, Haniyeh Saadati-Maleki, Sanaz Masoudi, Arash Ghasemi, Tohid Kazemi, Sahar Mehranfar, Manouchehr Fadaee

引用次数: 0